We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App





Ground-Breaking One-Step COVID-19 Cartridge May Enable Large-Scale Antibody Testing

By LabMedica International staff writers
Posted on 17 Aug 2020
A new one-step testing cartridge for COVID-19 antibody testing that will use a simplified procedure to eliminate operator error and deliver more consistent results will begin clinical studies by October.

The ground-breaking cartridge is being developed by Vivera Pharmaceuticals, Inc. More...
(Newport Beach, CA, USA), a pharmaceutical company focused on novel therapies for a variety of indications. To be tested, the user will simply obtain a drop of blood with a safety lancet and apply it directly on the cartridge. Upon closing the cartridge, the integrated blood flow system will automatically deliver the required amount of blood to the sample well, all while the internal buffer solution automatically releases, providing the exact volume of buffer needed for the test. Vivera is currently in discussions with top telemedicine providers in the US to develop effective testing protocols for the one-step cartridge once the FDA provides the appropriate pathways.

"The advantage of this new one-step testing cartridge is the simplification of the entire testing process," said Dr. Mehdi Hatamian, Vivera Pharmaceuticals Chief Scientific Advisor. "This technology will eventually allow for large-scale COVID-19 antibody testing and pave the way for future testing devices designed to greatly reduce the risk of human error."

"A consistent, user friendly, testing device will prove to be a vital tool for use not only at the point-of-care by medical professionals, but will open the door to the convenience of at-home testing for all," said Dr. Stephen McColgan Vivera Pharmaceuticals Chief Medical Officer. "As the world waits for a COVID-19 vaccine, we know that screening with antibody tests is the best way to help make more informed public health decisions."

"The availability of novel medical device technologies is exciting for the future expansion of our medical device division," said Paul Edalat Vivera Pharmaceuticals Chief Executive Officer. "A combination of innovative product development and strategic partnerships is really going to set Vivera apart in the coming months."

Related Links:

Vivera Pharmaceuticals, Inc.


Gold Member
Multiplex Genetic Analyzer
MassARRAY Dx Analyzer (Europe only)
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Alcohol Testing Device
Dräger Alcotest 7000
Laboratory Software
ArtelWare
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: Residual leukemia cells may predict long-term survival in acute myeloid leukemia (Photo courtesy of Shutterstock)

MRD Tests Could Predict Survival in Leukemia Patients

Acute myeloid leukemia is an aggressive blood cancer that disrupts normal blood cell production and often relapses even after intensive treatment. Clinicians currently lack early, reliable markers to predict... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.